Unichem Laboratories announced that the United States Food and Drug Administration (USFDA) has approved its Ranolazine extended-release tablets under an abbreviated new drug application (ANDA).
The approved ANDA is a generic version of Gilead Sciences Inc.’s Ranexa. Ranolazine extended-release tablets are used to treat chronic angina (chest pain). Unichem’s Goa plant will commercialise the product.
Unichem Laboratories is a global, integrated specialty pharmaceutical firm. It manufactures and sells a wide range of pharmaceutical formulations in a variety of markets around the world, both as branded generics and generics.